These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12352322)

  • 1. Angiotensin-converting enzyme inhibition and endothelin antagonism for endothelial dysfunction in heart failure: mono-or combination therapy.
    Bauersachs J; Fraccarollo D; Schäfer A; Ertl G
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):594-600. PubMed ID: 12352322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
    Bauersachs J; Heck M; Fraccarollo D; Hildemann SK; Ertl G; Wehling M; Christ M
    J Am Coll Cardiol; 2002 Jan; 39(2):351-8. PubMed ID: 11788231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism.
    Schäfer A; Fraccarollo D; Tas P; Schmidt I; Ertl G; Bauersachs J
    Eur J Heart Fail; 2004 Mar; 6(2):151-9. PubMed ID: 14984722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy.
    Mulder P; Boujedaini H; Richard V; Henry JP; Renet S; Münter K; Thuillez C
    Circulation; 2002 Aug; 106(9):1159-64. PubMed ID: 12196345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
    Schäfer A; Fraccarollo D; Hildemann SK; Tas P; Ertl G; Bauersachs J
    Cardiovasc Res; 2003 Jun; 58(3):655-62. PubMed ID: 12798439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy.
    Fraccarollo D; Bauersachs J; Kellner M; Galuppo P; Ertl G
    Cardiovasc Res; 2002 Apr; 54(1):85-94. PubMed ID: 12062365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure.
    Bauersachs J; Fraccarollo D; Galuppo P; Widder J; Ertl G
    Cardiovasc Res; 2000 Jul; 47(1):142-9. PubMed ID: 10869540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
    Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M
    J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models.
    Orth SR; Odoni G; Karkoszka H; Ogata H; Viedt C; Amann K; Ferrari P; Ritz E
    Nephrol Dial Transplant; 2003 Jan; 18(1):62-9. PubMed ID: 12480961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure.
    Thorin E; Lucas M; Cernacek P; Dupuis J
    Am J Physiol Heart Circ Physiol; 2000 Aug; 279(2):H844-51. PubMed ID: 10924085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent.
    Widder J; Behr T; Fraccarollo D; Hu K; Galuppo P; Tas P; Angermann CE; Ertl G; Bauersachs J
    Cardiovasc Res; 2004 Jul; 63(1):161-7. PubMed ID: 15194473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252.
    Bauersachs J; Braun C; Fraccarollo D; Widder J; Ertl G; Schilling L; Kirchengast M; Rohmeiss P
    J Hypertens; 2000 Oct; 18(10):1507-14. PubMed ID: 11057440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of chronic treatment with trandolapril on cyclic AMP-and cyclic GMP-dependent relaxations in aortic segments of rats with chronic heart failure.
    Toyoshima H; Nasa Y; Kohsaka Y; Isayama Y; Yamaguchi F; Sanbe A; Takeo S
    Br J Pharmacol; 1998 Jan; 123(2):344-52. PubMed ID: 9489624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat.
    Ezra-Nimni O; Ezra D; Peleg E; Munter K; Rosenthal T
    Am J Hypertens; 2003 Apr; 16(4):324-8. PubMed ID: 12670751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant nephropathy in a 'Fisher-to-Lewis' rat model.
    Adams J; Odoni G; Ogata H; Viedt C; Amann K; Ritz E; Orth SR
    Nephrol Dial Transplant; 2002 May; 17(5):780-7. PubMed ID: 11981063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats.
    Prié S; Leung TK; Cernacek P; Ryan JW; Dupuis J
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1312-8. PubMed ID: 9316840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition.
    Schäfer A; Fraccarollo D; Hildemann S; Christ M; Eigenthaler M; Kobsar A; Walter U; Bauersachs J
    Thromb Haemost; 2003 Jun; 89(6):1024-30. PubMed ID: 12783115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat.
    Hofman C; Gabai E; Peleg E; Munter K; Rosenthal T
    Blood Press; 2005; 14(2):114-9. PubMed ID: 16036489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
    Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
    Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.